62140-78-7Relevant articles and documents
Quinoxaline compound, preparation method and application of quinoxaline compound in medicine
-
, (2021/07/24)
The invention provides a quinoxaline compound, a preparation method and application of the quinoxaline compound in medicine, and particularly relates to a quinoxaline compound with PAR4 antagonistic activity, a preparation method of the quinoxaline compound, a pharmaceutical composition containing the quinoxaline compound and application of the quinoxaline compound. Specifically, the invention provides a compound shown as a general formula I and/or II or a tautomer or pharmaceutically acceptable salt thereof, a preparation method of the compound, and application of the compound or the tautomer or the pharmaceutically acceptable salt in medicines for preventing and/or treating thromboembolic diseases.
Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
-
Page 72, (2010/02/06)
Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.
Synthesis of 6,7-ethylenedioxyquinoxalines and pyrido[2,3-b]pyrazines as intermediates in the preparation of antineoplastic agents
Mateu,Capilla,Harrak,Pujol
, p. 5241 - 5250 (2007/10/03)
A convenient procedure for the synthesis of quinoxalines and pyridopyrazines has been developed from aryldiamines. The condensation of aminocarbamates such as 12 with ethyl 2,3-dibromopropionate provide the quinoxaline 14 directly, in a one-step operation. The methodology reported herein represents an alternative to condensation of o-phenylenediamines with α-dicarbonyl compounds for the quinoxalines formation. The same procedure was applied to the 2,3-diaminopyridine to obtain the corresponding pyridopyrazines.